CR20200392A - Anticuerpos anti-cd73 y métodos de uso de los mismos - Google Patents

Anticuerpos anti-cd73 y métodos de uso de los mismos

Info

Publication number
CR20200392A
CR20200392A CR20200392A CR20200392A CR20200392A CR 20200392 A CR20200392 A CR 20200392A CR 20200392 A CR20200392 A CR 20200392A CR 20200392 A CR20200392 A CR 20200392A CR 20200392 A CR20200392 A CR 20200392A
Authority
CR
Costa Rica
Prior art keywords
antibodies
methods
binding moiety
instant disclosure
tgfβ
Prior art date
Application number
CR20200392A
Other languages
English (en)
Inventor
Spencer Campbell
Jeremy Dale Waight
Oliver Schon
Shawn Michael Jennings
Benjamin Maxime Morin
Olga Ignatovich
Emmanuel Cyrille Pascal Briend
Nicholas Stuart Wilson
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of CR20200392A publication Critical patent/CR20200392A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente divulgación proporciona anticuerpos que se unen específicamente a CD73 (por ejemplo, CD73 humano) y antagonizan la función de CD73. También se proporcionan anticuerpos anti-CD73 que comprenden además 5 un resto de unión a TGFβ o un resto de unión a VEGF. La presente divulgación proporciona adicionalmente composiciones farmacéuticas que comprenden estos anticuerpos, ácidos nucleicos que codifican estos anticuerpos, vectores de expresión y células huésped para producir estos anticuerpos, y métodos para tratar a un sujeto usando estos anticuerpos.</p>
CR20200392A 2018-03-09 2019-03-08 Anticuerpos anti-cd73 y métodos de uso de los mismos CR20200392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862640850P 2018-03-09 2018-03-09
PCT/US2019/021313 WO2019173692A2 (en) 2018-03-09 2019-03-08 Anti-cd73 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
CR20200392A true CR20200392A (es) 2020-11-17

Family

ID=65904555

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200392A CR20200392A (es) 2018-03-09 2019-03-08 Anticuerpos anti-cd73 y métodos de uso de los mismos

Country Status (19)

Country Link
US (2) US11692042B2 (es)
EP (1) EP3762421A2 (es)
JP (2) JP7319992B2 (es)
KR (1) KR20200130403A (es)
CN (1) CN112074535A (es)
AR (1) AR114275A1 (es)
AU (2) AU2019231791B2 (es)
BR (1) BR112020017382A2 (es)
CA (1) CA3093468A1 (es)
CL (1) CL2020002314A1 (es)
CR (1) CR20200392A (es)
EA (1) EA202091710A1 (es)
IL (1) IL276731A (es)
MX (1) MX2020009394A (es)
PE (1) PE20210628A1 (es)
PH (1) PH12020551317A1 (es)
SG (1) SG11202007927WA (es)
TW (1) TWI823906B (es)
WO (1) WO2019173692A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2016104657A1 (ja) * 2014-12-26 2017-10-12 株式会社セラバイオファーマ 癌治療剤
PE20191208A1 (es) 2017-01-24 2019-09-10 I Mab Anticuerpos anti-cd73 y usos de los mismos
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
SG11202007927WA (en) 2018-03-09 2020-09-29 Agenus Inc Anti-cd73 antibodies and methods of use thereof
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CA3105721A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
BR112022003956A2 (pt) 2019-09-06 2022-05-24 Symphogen As Anticorpos anti-cd73
TW202124450A (zh) 2019-10-18 2021-07-01 美商四十七股份有限公司 用於治療骨髓發育不良症候群及急性骨髓白血病之組合療法
JP2022552748A (ja) 2019-10-31 2022-12-19 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
BR112022009317A2 (pt) * 2019-11-15 2022-08-09 Genzyme Corp Anticorpos de cd73 biparatópicos
WO2021130638A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
TW202138388A (zh) * 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
JP2023509442A (ja) 2020-01-03 2023-03-08 インサイト・コーポレイション Ｃｄ７３阻害剤とａ２ａ／ａ２ｂアデノシン受容体阻害剤の併用療法
EP4084825A1 (en) 2020-01-03 2022-11-09 Incyte Corporation Anti-cd73 antibodies and uses thereof
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021202642A2 (en) * 2020-04-01 2021-10-07 The Regents Of The University Of California Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
WO2021259199A1 (zh) * 2020-06-22 2021-12-30 信达生物制药(苏州)有限公司 抗cd73抗体及其用途
CN113817770B (zh) * 2020-08-12 2024-04-05 百奥赛图(北京)医药科技股份有限公司 Cd73基因人源化的非人动物的构建方法及应用
KR20230050378A (ko) * 2020-08-13 2023-04-14 이나뜨 파르마 에스.에이. 항-cd73 항체를 사용하여 암을 치료하는 방법
WO2022064399A1 (en) * 2020-09-23 2022-03-31 Medimmune, Llc Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20230416394A1 (en) * 2020-11-27 2023-12-28 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfbeta
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
WO2022179039A1 (zh) * 2021-02-24 2022-09-01 苏州近岸蛋白质科技股份有限公司 抗人cd73抗体及其应用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022256620A1 (en) * 2021-06-03 2022-12-08 The Broad Institute, Inc. Novel targets for enhancing anti-tumor immunity
JP2024521947A (ja) 2021-06-11 2024-06-04 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TW202315637A (zh) * 2021-06-11 2023-04-16 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
EP4116330A1 (en) * 2021-07-05 2023-01-11 Trion Research GmbH Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
JP2024524527A (ja) * 2021-07-05 2024-07-05 トリオン リサーチ ゲーエムベーハー がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体
CA3234909A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023154829A2 (en) * 2022-02-09 2023-08-17 Absci Corporation Unlocking de novo antibody design with generative artificial intelligence
WO2023164625A2 (en) * 2022-02-25 2023-08-31 Georgia Tech Research Corporation Modified plant virus system for delivery of nucleic acids into mammalian cells
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023246247A1 (zh) * 2022-06-22 2023-12-28 中山康方生物医药有限公司 药物组合物及其用途
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024010842A1 (en) * 2022-07-07 2024-01-11 The Board Of Trustees Of The Leland Stanford Junior University Targeting cells with a combination of cxcr2 inhibition and cd47 blockade
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU566788B2 (en) 1983-03-07 1987-10-29 Johnson, S.M. Monoclonal factor having 5:-nucleotidase inhibitory activity
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
ES2174868T3 (es) 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
DE69842174D1 (de) 1997-04-07 2011-04-21 Genentech Inc Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese
CN1257545A (zh) 1997-04-18 2000-06-21 拜奥根有限公司 Ⅱ型TGF－β受体/免疫球蛋白恒定区融合蛋白
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
DK1176981T3 (da) 1999-05-07 2006-04-10 Genentech Inc Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
KR20030016250A (ko) 2000-04-25 2003-02-26 아이덱 파마슈티칼즈 코포레이션 중추신경계 림프종 치료용 리툭시맵의 초내 투여
CN1330664C (zh) 2001-03-07 2007-08-08 默克专利有限公司 用于含杂合同种型抗体部分的蛋白质的表达技术
SI1613350T1 (sl) 2003-04-09 2009-08-31 Genentech Inc Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
US7786261B2 (en) 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
EP1824885A1 (en) 2004-12-17 2007-08-29 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
HUE042689T2 (hu) 2005-02-08 2019-07-29 Genzyme Corp TGFbéta elleni antitestek
RU2007142523A (ru) 2005-05-18 2009-06-27 БИОГЕН ИДЕК Инк. (US) Способы лечения фиброзных состояний
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
EP2078732B1 (en) 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
EP2578684B1 (en) 2007-03-19 2016-02-24 National Research Council Of Canada Antagonists of ligands and uses thereof
EP2171062A1 (en) 2007-06-15 2010-04-07 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
KR20110044992A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
CA2791383C (en) 2010-03-05 2022-09-20 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
USRE49280E1 (en) 2012-03-28 2022-11-08 Board Of Regents, The University Of Texas System TGFbeta type II-type III receptor fusions
CA3004695C (en) 2012-04-30 2020-08-04 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
WO2014164427A1 (en) 2013-03-12 2014-10-09 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
CN105452287A (zh) 2013-04-17 2016-03-30 贝勒医学院 免疫抑制性TGF-β信号转换器
WO2015006500A2 (en) 2013-07-09 2015-01-15 President And Fellows Of Harvard College Endothelial cell genes and uses thereof
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
EP3685848B1 (en) 2013-11-21 2021-09-15 The Brigham and Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
AR098827A1 (es) 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
CN113549159A (zh) 2014-02-10 2021-10-26 默克专利有限公司 靶向TGFβ抑制
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
CA2957813A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
JP6755866B2 (ja) 2014-11-10 2020-09-16 メディミューン リミテッド Ｃｄ７３特異的結合分子及びその使用
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
EP3259288A1 (en) * 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
SI3280727T1 (sl) 2015-04-06 2021-07-30 Acceleron Pharma Inc. Enoskupinske fuzijske beljakovine receptorjev tipa I in tipa II ter njihova uporaba
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
EP3344660A4 (en) 2015-08-31 2019-07-03 National Research Council of Canada TGF-BETA-RECEPTOR-EKTODOMÄNENFUSIONSMOLEKÜLE AND USES THEREOF
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
AU2016366548B2 (en) 2015-12-09 2023-12-14 Bioatla, Llc Humanized anti-CD73 antibodies
WO2017118613A1 (en) * 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73
WO2017134592A1 (en) 2016-02-03 2017-08-10 Biocon Limited Anti-cd20/immunomodulatory fusion proteins and methods for making same
MY191649A (en) 2016-03-04 2022-07-05 Jn Biosciences Llc Antibodies to tigit
US20190284293A1 (en) 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017167921A1 (en) 2016-03-30 2017-10-05 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
CN109414500B (zh) 2016-06-13 2022-02-25 奥美药业有限公司 治疗和诊断用pd-l1特异性单克隆抗体
WO2018013611A1 (en) * 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
US11180554B2 (en) 2016-12-13 2021-11-23 Astellas Pharma Inc. Anti-human CD73 antibody
PE20191208A1 (es) 2017-01-24 2019-09-10 I Mab Anticuerpos anti-cd73 y usos de los mismos
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
SG11202007927WA (en) 2018-03-09 2020-09-29 Agenus Inc Anti-cd73 antibodies and methods of use thereof

Also Published As

Publication number Publication date
KR20200130403A (ko) 2020-11-18
EP3762421A2 (en) 2021-01-13
US20230416397A1 (en) 2023-12-28
PE20210628A1 (es) 2021-03-23
CN112074535A (zh) 2020-12-11
PH12020551317A1 (en) 2021-09-01
US20190352418A1 (en) 2019-11-21
AU2022259823A1 (en) 2022-12-01
AU2019231791B2 (en) 2022-08-11
AU2019231791A1 (en) 2020-09-03
WO2019173692A3 (en) 2019-11-14
US11692042B2 (en) 2023-07-04
WO2019173692A2 (en) 2019-09-12
JP7319992B2 (ja) 2023-08-02
CA3093468A1 (en) 2019-09-12
MX2020009394A (es) 2021-01-15
AR114275A1 (es) 2020-08-12
SG11202007927WA (en) 2020-09-29
JP2023129543A (ja) 2023-09-14
TW201945391A (zh) 2019-12-01
JP2021515559A (ja) 2021-06-24
CL2020002314A1 (es) 2021-03-05
IL276731A (en) 2020-09-30
TWI823906B (zh) 2023-12-01
EA202091710A1 (ru) 2021-02-16
BR112020017382A2 (pt) 2021-01-26

Similar Documents

Publication Publication Date Title
CR20200392A (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
EP4275698A3 (en) Anti-tigit antibodies and methods of use thereof
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
MX2020004578A (es) Composiciones de casz y metodos de uso.
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
MX2018002315A (es) Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
SA522432917B1 (ar) ميوتينات إنترليوكين-21 وطرق العلاج
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2022002315A (es) Anticuerpos anti-cd96 y sus metodos de uso.
MX2019003058A (es) Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1).
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
WO2020070678A3 (en) Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
MX2023012707A (es) Anticuerpos de la proteina inmunorreceptora de celulas t con dominios ig e itim (anti-tigit) y metodos de uso de estos.
MX2023013078A (es) Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.
EA201990927A1 (ru) Антитела против lag-3 и способы их применения